• All
• Day 1: March 27 (Thu)
• Day 2: March 28 (Fri)
• Day 3: March 29 (Sat)

Day 1: March 27 (Thu)

• Opportunities and challenges in managing adult ALL in Vietnam Han Viet Trung
  Bach Mai Hospital, Vietnam CV Abstract
• Adult ALL in Armenia Armine Farmazyan
  Hematology center after Prof. Yeolyan, Armenia CV Abstract
• Clinical features, genetic profiling and treatment outcomes of adult acute lymphoblastic leukemia: A prospective multicenter study in Thailand Weerapat Owattanapanich
  Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand CV Abstract
• Adult ALL in Korea Ik-Chan Song
  Chungnam National University College of Medicine, Korea CV Abstract

Day 1: March 27 (Thu)

• Diagnosis and treatment of Ph-like ALL in children and young adults Thai Hoa Tran
  Université de Montréal, Canada CV Abstract
• Advances in the genetics of down syndrome-related myeloid leukemias Etsuro Ito
  Hirosaki University Graduate School of Medicine, Japan CV Abstract
• Towards improving outcomes for high risk pediatric acute myeloid leukemia Todd Cooper
  Seattle Children’s Hospital Cancer and Blood Disorders Service, USA CV

Day 1: March 27 (Thu)

• Immune therapy and the bone marrow microenvironment in multiple myeloma Hearn Jay Cho
  Icahn School of Medicine at Mount Sinai, USA CV Abstract
• Mechanisms of antigen escape after T-cell based immunotherapies Paola Neri
  University of Calgary, Canada CV Abstract
• Cellular immunotherapy platforms in multiple myeloma Sung-Hoon Jung
  Chonnam National University Medical School, Korea CV

Day 1: March 27 (Thu)

• Tracing the changes: MDS risk stratification Seo-Yeon Ahn
  Chonnam National University Medical School, Korea CV
• Managing MDS with HMAs following the AZA-001 trial Silvia Park
  College of Medicine, The Catholic University of Korea, Korea CV
• Approved MDS treatments beyond HMAs Junshik Hong
  Seoul National University College of Medicine, Korea CV

Day 1: March 27 (Thu)

• Myeloproliferative Neoplasms: 2025 update Ayalew Tefferi
  Mayo Clinic, USA CV

Day 1: March 27 (Thu)

• CAR T-cell therapy for Lymphomas: Current and future trends Sattva S Neelapu
  The University of Texas MD Anderson Cancer Center, USA CV Abstract

Day 1: March 27 (Thu)

• Altered transcriptional programmes in AML: The role of aberrant gene regulatory complexes (GRC) Brian Huntly
  University of Cambridge, UK Abstract
• Treatment of AML in Korea June-Won Cheong
  Yonsei University College of Medicine, Korea
• Genetics guiding treatment in AML Hartmut Döhner
  Ulm University Hospital, Germany CV
• The dynamic landscape of AML genetics: From the perspective of the Korean AML/MDS working party study Jae-Sook Ahn
  Chonnam National University Medical School, Korea CV

Day 1: March 27 (Thu)

• How to decide and treat when DOAC should not be standard treatment Jeffrey I. Weitz
  McMaster University, Canada CV
• Managing patients with cancer associated venous thromboembolism Robert D. McBane II
  Mayo College of Medicine, USA CV Abstract
• Risk assessment and thromboprophylaxis for cancer-associated VTE Ingrid Pabinger-Fasching
  Medical University of Vienna, Austria CV

Day 1: March 27 (Thu)

• Peripheral T-cell lymphoma: From biology to practice Owen A O'Connor
  University of Virginia Comprehensive Cancer Center, USA CV
• Recent updates and future in the management of R/R PTCL Won Seog Kim
  Sungkyunkwan University School of Medicine, Korea CV
• The development of new agents in T-cell lymphoma Hyun Jung Lee
  Kyung Hee University College of Medicine, Korea

Day 1: March 27 (Thu)

• AI everywhere Auk Kim
  Department of Computer Science and Engineering, Kangwon National University, Korea CV Abstract
• Revolutionizing medical documentation: Leveraging ChatGPT and RAG frameworks for optimized scientific writing and clinical interpretation Sang-Hyun Hwang
  University of Ulsan College of Medicine, Korea CV Abstract
• Generative AI use case for medical research: HRS (Healthcare data research suite) Soo-Yong Shin
  Head of Research & Chief Privacy Officer, KakaoHealthcare, Korea CV Abstract

Day 1: March 27 (Thu)

• Iron metabolism in JAK2-mutant myeloproliferative neoplasm Radek C. Skoda
  Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, USA CV Abstract
• Hepcidin in the pathophysiology of and as treatment for polycythemia vera Yelena Z. Ginzburg
  Icahn School of Medicine at Mount Sinai, USA CV Abstract
• Anemia and JAK inhibitors Jean-Jaques Kiladjian
  Saint-Louis Hospital, France CV Abstract

Day 1: March 27 (Thu)

• Innovations in HLH therapy: Beyond HLH94 Michelle Hermiston
  University of California San Francisco, USA
• Navigating pediatric histiocytosis: Advances in first-line MAPK inhibition and targeted therapies Oussama Abla
  The Hospital for Sick Children, Canada CV Abstract
• From CRS to IEC-HS: Advancements in understanding and treating hemophagocytic syndromes Melissa Hines
  St. Jude Children’s Research Hospital , USA CV Abstract

Day 1: March 27 (Thu)

• Understanding and overcoming resistance in AML: Targeted therapy barriers Dong-Yeop Shin
  College of Medicine, The Catholic University of Korea, Korea CV
• Exploring immune checkpoint targets beyond PD-1 and PD-L1 in AML Tae Kon Kim
  Vanderbilt University Medical Center, USA CV Abstract
• Implementing a functional precision medicine for AML patients Mika Kontro
  Helsinki University Hospital, Finland CV Abstract

Day 1: March 27 (Thu)

• Crafting a successful investigator-initiated study proposal: Key elements and strategies Young Woo Jeon
  College of Medicine, The Catholic University of Korea, Korea
• Current Trends of Big Data Research Using the Korean National Health Information Database Kyung-Do Han
  Department of Statistics and Actuarial Science, Soongsil University, Korea CV
• Phase-specific strategies for adverse events management in clinical trials: Best practices in AE documentation and reporting Jeong-Ok Lee
  Seoul National University College of Medicine, Korea Abstract

Day 2: March 28 (Fri)

• Beyond BCR::ABL1-The Role of Genomic Analysis in the Management of CML Susan Branford
  Centre for Cancer Biology, SA Pathology, Australia CV Abstract
• Next-Generation Sequencing (NGS) in CML Jieun Kim
  Soonchunhyang University College of Medicine, Korea CV
• What systems biology and AI can teach us about the pathogenesis and therapy of CML Richard A. Van Etten
  University of California Irvine, USA CV
• Beyond BCR::ABL1 RQ-PCR in CML Hawk Kim
  Gachon University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Chronic inflammation as a driver of TP53-mutant leukemic evolution Yan Liu
  Northwestern University Feinberg School of Medicine, USA CV Abstract
• TP53 copy number and protein expression for risk stratification in AML Joseph D. Khoury
  University of Nebraska Medical Center, USA CV
• Molecular characterization of TP53 mutation in AML and high-risk MDS Peter J.M. Valk
  Erasmus MC Cancer Institute, The Netherlands CV Abstract

Day 2: March 28 (Fri)

• Is it time to embrace Chemotherapy-Free Regimens in Ph+ ALL Jae-ho Yoon
  College of Medicine, The Catholic University of Korea, Korea CV
• CAR T-Cell Therapy in relapsed/refractory Acute Lymphoblastic Leukemia Jae Park
  Memorial Sloan Kettering Cancer Center, USA CV
• Navigating new horizons: Safety and efficacy of CD7-CAR-T cells in T-ALL/LBL Yongxian Hu
  The First Affiliated Hospital of College of Medicine, Zhejiang University, China CV Abstract

Day 2: March 28 (Fri)

• MRD-based therapeutic decisions in AML Dae Hun Kwag
  College of Medicine, The Catholic University of Korea, Korea CV
• MRD-based therapeutic decisions in pediatric ALL Jung Yoon Choi
  Seoul National University College of Medicine, Korea CV
• MRD-based therapeutic decisions in MM Ji Hyun Lee
  Dong-A University College of Medicine, Korea CV

Day 2: March 28 (Fri)

• From ancient origins to modern tools: CD38's evolutionary legacy in science and clinical practice Fabio Malavasi
  University of Torino, Italy CV

Day 2: March 28 (Fri)

• Treatment strategies for transplant-eligible newly diagnosed multiple myeloma Ja Min Byun
  Seoul National University College of Medicine, Korea CV Abstract
• Treatment of transplant-ineligible MM Jongheon Jung
  National Cancer Center, Korea CV
• Supportive care of multiple myeloma patients in the new agent era: Optimizing outcomes beyond therapy Sung-Soo Park
  College of Medicine, The Catholic University of Korea CV Abstract

Day 2: March 28 (Fri)

• Overcoming aggressive pediatric non-hodgkin lymphoma Birgit Burkhardt
  University Hospital Münster, Germany CV Abstract
• Utilizing NGS MRD as an effective tool in ALL management Yongmin Tang
  Children’s Hospital of Zhejiang University School of Medicine, China CV Abstract
• CAEBV, from basic to updated therapeutic options Seung Min Hahn
  Yonsei University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Current status of "off-the-shelf" allogeneic CAR in the treatment of acute lymphoblastic leukemia Reuben Benjamin
  King’s College London, UK CV
• Allogeneic CAR-T cells engineered with gene-editing strategies for the treatment of B-cell non-Hodgkin lymphomas Boyu Hu
  University of Utah, USA CV Abstract
• Memory-like NK cells armed with a neoantigen-specific CAR Rizwan Romee
  Harvard Medical School, USA CV

Day 2: March 28 (Fri)

• Anemia Eun sang Yu
  Korea University College of Medicine, Korea CV
• Thrombocytopenia Yoo Jin Lee
  Ulsan University Hospital, Korea CV
• Neutropenia Seonggyu Byeon
  Gachon University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Current status of CAR-T treatment in Taiwan Tai-Chung Huang
  National Taiwan University Hospital, Taiwan CV
• Challenges in CAR-T treatment in Singapore William YK Hwang
  National Cancer Centre Singapore, Singapore CV
• Barriers and paths in CAR-T therapy in China Kailin Xu
  The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China CV
• Present and future of CAR-T therapy in Korea Dok Hyun Yoon
  University of Ulsan College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• NGS-based MRD in AML James L. Zehnder
  Stanford University School of Medicine, USA CV
• Exploring the transcriptional and protein landscape of immune cells with CITE-seq Jennifer A. Foltz
  Washington University School of Medicine, USA CV Abstract
• CML drug resistance profiling using CRISPR-Cas9 Hyongbum Henry Kim
  Yonsei University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Finding a better immunosuppressive treatment in SAA Fengkui Zhang
  Chinese Academy of Medical Sciences and Peking Union Medical College, China CV Abstract
• Alternative donor HSCT in SAA Ho Joon Im
  University of Ulsan College of Medicine, Korea CV
• Optimal treatment of PNH in the era of proximal complement inhibitors Rosario Notaro
  Core Research Laboratory, ISPRO, Italy CV

Day 2: March 28 (Fri)

• Immunotherapy in follicular lymphoma Gi June Min
  College of Medicine, The Catholic University of Korea, Korea CV
• BTK inhibitions in waldenstroms macroglobulinemia Myung-won Lee
  Chungnam National University College of Medicine, Korea CV
• Treatment for older patients with Hodgkin lymphoma Hyunsoo Cho
  Yonsei University College of Medicine, Korea CV

Day 3: March 29 (Sat)

• Current status of MRD assessment in Japan Hiroyuki Takamatsu
  Kanazawa University, Japan CV
• Current status of MRD assessment in Korea Saeam Shin
  Yonsei University College of Medicine, Korea CV Abstract
• Immunotherapy (bispecific Abs or CAR-T therapy) for MM in Japan Tadao Ishida
  Japanese Red Cross Medical Center, Japan CV Abstract
• Real-world efficacy and safety of teclistamab for patients with released or refractory multiple myeloma: Korean, nationwide, retrospective analysis Jun Ho Yi
  Chung-Ang University College of Medicine, Korea CV

Day 3: March 29 (Sat)

• Investigative approaches to unexplained bleeding Alessandro Casini
  University Hospitals of Geneva, Switzerland CV Abstract
• Optimal testing strategies for suspected platelet disorders Christopher Ward
  University of Sydney, Australia CV Abstract
• Thrombophilia testing in clinical practice: Indications, challenges, and current approaches Hee-Jin Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day 3: March 29 (Sat)

• Advancing CD3xCD20 bispecific Abs: Integration in first-line treatment of DLBCL  Catherine Thieblemont
  Hôpital Saint-Louis, France CV
• Emerging bispecific antibodies for B-Cell lymphoma: New targets and future directions Youngil Koh
  Seoul National University College of Medicine, Korea CV
• Management of toxicity of bispecific antibody for B-cell lymphomas Koji Izutsu
  National Cancer Center Hospital, Japan CV Abstract

Day 3: March 29 (Sat)

• Invasive fungal infections in hematologic disease: Prophylaxis and treatment Sung-Yeon Cho
  College of Medicine, The Catholic University of Korea, Korea CV
• CMV infections after HSCT: Prophylaxis and treatment Haerim Chung
  Yonsei University College of Medicine, Korea CV
• Iron overload and iron chelation therapy Ga-Young Song
  Chonnam National University Medical School, Korea CV Abstract

Day 3: March 29 (Sat)

• New discoveries that will shape future therapies in Chronic Myeloid Leukemia Timothy Hughes
  South Australian Health and Medical Research Institute (SAHMRI), Australia CV Abstract